2016
Change in attitudes and knowledge of problem drug use and harm reduction among a community cohort in Kabul, Afghanistan.
Todd C, Stanekzai M, Nasir A, Fiekert K, Orr M, Strathdee S, Vlahov D. Change in attitudes and knowledge of problem drug use and harm reduction among a community cohort in Kabul, Afghanistan. Eastern Mediterranean Health Journal 2016, 22: 183-92. PMID: 27334075, DOI: 10.26719/2016.22.3.183.Peer-Reviewed Original ResearchConceptsDrug usersHarm reductionProvision of condomsPre-post evaluationCommunity cohortDrug treatmentProblem drug useSyringe distributionFurther community educationDrug useInterview questionnaireConvenience sampleMedical professionalsAgreement levelCommunity educationCommunity representativesDrug policyCommunity supportPeriod of expansionAfghanistanProfessionalsCohortCondomsKabul
2008
Prevalence and Correlates of Previous Hepatitis B Vaccination and Infection Among Young Drug-users In New York City
Amesty S, Ompad D, Galea S, Fuller C, Wu Y, Koblin B, Vlahov D. Prevalence and Correlates of Previous Hepatitis B Vaccination and Infection Among Young Drug-users In New York City. Journal Of Community Health 2008, 33: 139-148. PMID: 18185987, DOI: 10.1007/s10900-007-9082-4.Peer-Reviewed Original ResearchConceptsEvidence of infectionHBV vaccinationPrevious vaccinationSerological evidenceHepatitis B vaccination coveragePrevious hepatitis B vaccinationPrevious HBV infectionPrevious HBV vaccinationHepatitis B vaccinationHepatitis B vaccineHigh-risk groupYears of ageCommunity-based sampleB vaccinationHBV infectionB vaccineVaccination statusVaccination coverageRisk groupsHigh school educationVaccinationSusceptible individualsDrug usersInfection rateBivariate analysis
2007
Identifying injection drug users at risk of nonfatal overdose.
Coffin P, Tracy M, Bucciarelli A, Ompad D, Vlahov D, Galea S. Identifying injection drug users at risk of nonfatal overdose. Academic Emergency Medicine 2007, 14: 616-23. PMID: 17554010, DOI: 10.1197/j.aem.2007.04.005.Peer-Reviewed Original ResearchConceptsDrug usersHabitual drug usersNonfatal overdoseAggressive prevention effortsAgonist maintenance treatmentSerious withdrawal symptomsInjection drug usersFurther longitudinal studiesIndividual-level risk factorsTake-home naloxoneOverdose prevention interventionsFuture overdosesMaintenance treatmentWithdrawal symptomsRisk factorsDrug overdoseRecent overdoseEmergency physiciansOverdose riskPrevention interventionsHigh riskOverdoseMedical careYounger ageU.S. adultsEarly immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users
Mehta S, Lucas G, Astemborski J, Kirk G, Vlahov D, Galai N. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care 2007, 19: 637-645. PMID: 17505924, DOI: 10.1080/09540120701235644.Peer-Reviewed Original ResearchConceptsInjection drug usersActive antiretroviral therapyRisk of progressionVirologic responseTreatment interruptionImmunologic responseAntiretroviral therapyCommunity-based injection drug usersDrug usersMultiple Cox regression analysisRecent outpatient visitYears of HAARTCox regression analysisInjection drug useNew AIDS diagnosesSubsequent disease progressionEarly responseHAART initiationHAART initiatorsHIV careOutpatient visitsCox regressionPrognostic valueAIDS diagnosisPoor response
2006
Physical activity in a cohort of HIV-positive and HIV-negative injection drug users
Smit E, Crespo C, Semba R, Jaworowicz D, Vlahov D, Ricketts E, Ramirez-Marrero F, Tang A. Physical activity in a cohort of HIV-positive and HIV-negative injection drug users. AIDS Care 2006, 18: 1040-1045. PMID: 17012097, DOI: 10.1080/09540120600580926.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV-positive participantsHIV-positive injection drug usersInjection drug useHIV-negativeVigorous activityPhysical activityDrug usersDrug usePaffenbarger Physical Activity QuestionnaireRecent injection drug usersHIV-negative injection drug usersIntravenous Experience cohortActive antiretroviral therapyCohort of HIVHIV-negative participantsPhysical Activity QuestionnairePhysical activity levelsAntiretroviral therapyHIV infectionViral loadHIV treatmentActivity QuestionnaireAnthropometric measurementsEnergy expenditureThe Nonimpact of the Expanded Syringe Access Program upon Heroin Use, Injection Behaviours, and Crime Indicators in New York City and State
Johnson B, Golub A, Deren S, Jarlais D, Fuller C, Vlahov D. The Nonimpact of the Expanded Syringe Access Program upon Heroin Use, Injection Behaviours, and Crime Indicators in New York City and State. Justice Research And Policy 2006, 8: 27-49. DOI: 10.3818/jrp.8.1.2006.27.Peer-Reviewed Original ResearchSyringe access programsHeroin useDrug usersAccess programInjection drug usersBlood-borne diseasesHealth care providersIllicit drug usersExpanded Syringe Access ProgramHepatitis C.Drug injectionDrug treatmentCare providersClean syringesSyringe accessSubstance abuseNew York StateLarger evaluationSyringesInjection behaviorNew York CityHIVYork CityDisease
2005
Injection Drug Use Is an Independent Risk Factor for Iron Deficiency and Iron Deficiency Anemia Among HIV-Seropositive and HIV-Seronegative Women
Dancheck B, Tang A, Thomas A, Smit E, Vlahov D, Semba R. Injection Drug Use Is an Independent Risk Factor for Iron Deficiency and Iron Deficiency Anemia Among HIV-Seropositive and HIV-Seronegative Women. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2005, 40: 198-201. PMID: 16186738, DOI: 10.1097/01.qai.0000165909.12333.07.Peer-Reviewed Original ResearchConceptsInjection drug useIron deficiency anemiaHepatitis C virus statusFemale injection drug usersC virus statusInjection drug usersDeficiency anemiaDrug useIron deficiencyRisk factorsVirus statusDrug usersMultivariate analysisInjection drug use historyCD4 lymphocyte countHIV-seronegative womenIndependent risk factorHIV-positive womenCross-sectional studyFurther longitudinal studiesNatural history studiesIntravenous Experience (ALIVE) studyDrug use historyHIV-seropositiveLymphocyte countLiver enzyme values in injection drug users with chronic hepatitis C
Mehta S, Netski D, Sulkowski M, Strathdee S, Vlahov D, Thomas D. Liver enzyme values in injection drug users with chronic hepatitis C. Digestive And Liver Disease 2005, 37: 674-680. PMID: 15951255, DOI: 10.1016/j.dld.2005.03.009.Peer-Reviewed Original ResearchConceptsHepatitis C virusHepatitis C virus-infected personsAcute viral hepatitisLiver enzyme valuesVirus-infected personsC virusAminotransferase levelsViral hepatitisAlanine aminotransferaseAlanine aminotransferase/aspartate aminotransferase ratioChronic hepatitis C virus (HCV) infectionEnzyme valuesHepatitis C virus infectionAspartate aminotransferase ratioC virus infectionChronic hepatitis CHigher alanine aminotransferaseInjection drug usersHepatitis CAminotransferase ratioSerologic testingLiver enzymesULNVirus infectionDrug usersSexual Risk Behavior Among Injection Drug Users Before Widespread Availability of Highly Active Antiretroviral Therapy
Rusch M, Farzadegan H, Tarwater P, Safaeian M, Vlahov D, Strathdee S. Sexual Risk Behavior Among Injection Drug Users Before Widespread Availability of Highly Active Antiretroviral Therapy. AIDS And Behavior 2005, 9: 289-299. PMID: 16133905, DOI: 10.1007/s10461-005-9003-4.Peer-Reviewed Original ResearchConceptsInjection drug usersCondom useAntiretroviral therapyHIV testingDrug usersEligible injection drug usersRisk behaviorsActive antiretroviral therapyInconsistent condom useSexual risk behaviorsIDU cohortHIV transmissionRetrospective analysisLower riskStudy exposureSexual riskLong-term studiesTherapySignificant changesCounselingRiskExposureLogistic modelWidespread availabilityCohort556-S: Factors Associated with the use of ‘Street Methadone’ by HIV-Seropositive Injection Drug users in Four Us Cities
Gern R, Eldred L, Gourevitch M, Metsch L, Latkin C, Gomez C, Vlahov D. 556-S: Factors Associated with the use of ‘Street Methadone’ by HIV-Seropositive Injection Drug users in Four Us Cities. American Journal Of Epidemiology 2005, 161: s139-s139. DOI: 10.1093/aje/161.supplement_1.s139c.Peer-Reviewed Original ResearchSuicidal ideation among African-American non-injection drug users.
Havens J, Ompad D, Latkin C, Fuller C, Arria A, Vlahov D, Strathdee S. Suicidal ideation among African-American non-injection drug users. Ethnicity & Disease 2005, 15: 110-5. PMID: 15720057.Peer-Reviewed Original ResearchConceptsSuicidal ideationDrug usersDrug dependenceNon-injection drug usersCommunity-based cohortInterview-administered questionnaireMultiple logistic regressionDrug use historyUse of heroinAfrican American drug usersMedian agePsychiatric comorbidityDepressive symptomsMore drugsSuicidal thoughtsLogistic regressionIdeationAfrican AmericansUse historyParticipantsComorbiditiesCohortSymptomsYearsHeroin
2004
Acceptance and completion of hepatitis B vaccination among drug users in New York City.
Ompad D, Galea S, Wu Y, Fuller C, Latka M, Koblin B, Vlahov D. Acceptance and completion of hepatitis B vaccination among drug users in New York City. Communicable Disease And Public Health 2004, 7: 294-300. PMID: 15779793.Peer-Reviewed Original ResearchConceptsDrug usersVaccine acceptanceHepatitis B vaccination ratesNon-injecting drug usersDaily crack usersPrevious HBV infectionHepatitis B vaccinationB vaccination ratesOngoing prospective studyB vaccinationDaily injectorsHBV testingHBV vaccinationVaccination seriesVaccine acceptorsHBV infectionVaccine seriesPrevious vaccinationRisk behavior questionnaireProspective studyVaccination acceptanceVaccination ratesSerological evidenceSeries completionVaccinationComparison of HIV infection risk behaviors among injection drug users from East and West Coast US cities
Garfein R, Monterroso E, Tong T, Vlahov D, Des Jarlais D, Selwyn P, Kerndt P, Word C, Fernando M, Ouellet L, Holmberg S. Comparison of HIV infection risk behaviors among injection drug users from East and West Coast US cities. Journal Of Urban Health 2004, 81: 260-267. PMID: 15136659, PMCID: PMC3456450, DOI: 10.1093/jurban/jth112.Peer-Reviewed Original ResearchConceptsInjection drug usersRisk behaviorsHIV seroprevalenceHigh human immunodeficiency virus (HIV) seroprevalenceDrug usersHIV infection risk behaviorsHuman immunodeficiency virus (HIV) seroprevalenceInfection risk behaviorsPotential risk factorsHIV risk behaviorsHIV incidenceHIV statusRisk factorsVirus seroprevalenceSexual partnersPrevention effortsSeroprevalenceBaseline dataHIVFace interviewsInjectionNew York CityFurther effortsNew HavenParticipantsIncrease in Sexual Risk Behavior Associated with Immunologic Response to Highly Active Antiretroviral Therapy among HIV-Infected Injection Drug Users
Tun W, Gange S, Vlahov D, Strathdee S, Celentano D. Increase in Sexual Risk Behavior Associated with Immunologic Response to Highly Active Antiretroviral Therapy among HIV-Infected Injection Drug Users. Clinical Infectious Diseases 2004, 38: 1167-1174. PMID: 15095224, DOI: 10.1086/383033.Peer-Reviewed Original ResearchConceptsInjection drug usersActive antiretroviral therapyHAART initiationCell countAntiretroviral therapyDrug usersSexual intercourseRisk reduction counselingHuman immunodeficiency virusLarge cohort studyDrug injection behaviorInjection of drugsUnprotected sexual intercourseSemiannual visitsReduction counselingCohort studyHIV infectionHIV serostatusImmunodeficiency virusImmunologic responseNeedle sharingBlood samplesSurvival analysisRisk behaviorsCD4Hepatitis C incidence—a comparison between injection and noninjection drug users in New York City
Fuller C, Ompad D, Galea S, Wu Y, Koblin B, Vlahov D. Hepatitis C incidence—a comparison between injection and noninjection drug users in New York City. Journal Of Urban Health 2004, 81: 20-24. PMID: 15047780, PMCID: PMC3456148, DOI: 10.1093/jurban/jth084.Peer-Reviewed Original ResearchConceptsHepatitis C virusInjection drug usersNoninjection drug usersDrug usersHCV seropositiveRisk of HCVNew injection drug usersPerson-time analysisAnnual incidence rateHepatitis C incidenceAnnual incident rateHigh-risk practicesHCV incidenceHCV seroconvertersNon-IDUsHCV serologyHCV preventionC virusRisk factorsIncidence ratePrevention servicesOnset of injectionEarly preventionNew York CityRisk Survey
2003
Retinoids and Drugs of Abuse: Implications for Neurological Disease Risk in Human Immunodeficiency Virus Type 1 Infection
Royal W, Vlahov D, Lyles C, Gajewski C. Retinoids and Drugs of Abuse: Implications for Neurological Disease Risk in Human Immunodeficiency Virus Type 1 Infection. Clinical Infectious Diseases 2003, 37: s427-s432. PMID: 14648459, DOI: 10.1086/377554.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1 (HIV-1) infectionVirus type 1 infectionType 1 infectionDrug usersSeronegative control subjectsRetinoic acidDevelopment of HIVInjection drug usersTumor necrosis factorNervous system diseasesLevels of retinolMononuclear cell lineNeurological disease riskTrans retinoic acidDrugs of abuseRetinoid administrationClinical outcomesRetinol-binding proteinImmunomodulatory effectsControl subjectsNecrosis factorSystem diseasesNeurological diseasesHIVDisease riskLongitudinal Patterns of Drug Injection Behavior in the ALIVE Study Cohort,1988–2000: Description and Determinants
Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano D. Longitudinal Patterns of Drug Injection Behavior in the ALIVE Study Cohort,1988–2000: Description and Determinants. American Journal Of Epidemiology 2003, 158: 695-704. PMID: 14507606, DOI: 10.1093/aje/kwg209.Peer-Reviewed Original ResearchConceptsInjection drug usersDrug injection behaviorDrug usersIntravenous Experience (ALIVE) studyDrug treatment programsHistory of incarcerationLogistic regression modelsALIVE studySemiannual visitsMultinomial logistic regression modelsBaseline factorsChronic diseasesDrug injectionRecent overdoseCessation attemptsDrug use transitionsDrug injectorsCommunity outreach effortsLongitudinal patternsHigh mortalityEarly determinantsYounger ageTreatment programInjection behaviorStudy periodThe Role of Medicaid HMO Enrollment in the Longitudinal Utilization of Medical Care Services in a Cohort of Injecting Drug users in Baltimore, Maryland
Juday T, Wu A, Celentano D, Rick K, Wang M, Vlahov D. The Role of Medicaid HMO Enrollment in the Longitudinal Utilization of Medical Care Services in a Cohort of Injecting Drug users in Baltimore, Maryland. Substance Abuse 2003, 24: 27-41. PMID: 12652093, DOI: 10.1080/08897070309511531.Peer-Reviewed Original ResearchConceptsAmbulatory care visitsCare visitsInpatient admissionsHMO enrollmentDrug usersMedicaid HMO enrolleesMore inpatient admissionsInjecting Drug UsersMedical care utilizationNatural history studiesIntravenous Experience (ALIVE) studyMedical care servicesCommunity-based sampleLongitudinal utilizationER visitsHIV infectionCare utilizationMedicaid beneficiariesHMO enrolleesCare servicesIDUsInappropriate utilizationUtilization differencesMedicaidMedicaid HMOsVariability in the Incidence of Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection among Young Injecting Drug Users in New York City
Des Jarlais D, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, Rockwell R, Edwards V, Friedman S, Monterroso E, Williams I, Garfein R. Variability in the Incidence of Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection among Young Injecting Drug Users in New York City. American Journal Of Epidemiology 2003, 157: 467-471. PMID: 12615611, DOI: 10.1093/aje/kwf222.Peer-Reviewed Original ResearchConceptsHepatitis B virusHuman immunodeficiency virusHepatitis C virusImmunodeficiency virusB virusDrug usersHepatitis C virus infectionC virus infectionInjecting Drug UsersHigh HIV seroprevalenceHigh rateHBV incidenceHCV incidenceHCV transmissionCohort studyHIV seroprevalenceHIV incidenceHIV transmissionYoung Injecting Drug UsersC virusVirus infectionNew York CityIncidenceVirusYork CityFeasibility of referring drug users from a needle exchange program into an addiction treatment program: Experience with a mobile treatment van and LAAM maintenance
Kuo I, Brady J, Butler C, Schwartz R, Brooner R, Vlahov D, Strathdee S. Feasibility of referring drug users from a needle exchange program into an addiction treatment program: Experience with a mobile treatment van and LAAM maintenance. Journal Of Substance Use And Addiction Treatment 2003, 24: 67-74. PMID: 12646332, DOI: 10.1016/s0740-5472(02)00343-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultBaltimoreCocaine-Related DisordersFeasibility StudiesFemaleHeroin DependenceHumansMaleMethadyl AcetateMobile Health UnitsNarcoticsNeedle-Exchange ProgramsReferral and ConsultationSeverity of Illness IndexSubstance Abuse Treatment CentersSubstance-Related DisordersTime FactorsTreatment OutcomeConceptsTreatment programLevomethadyl acetate hydrochlorideFirst-line treatmentEarly treatment responseNeedle exchange programsCocaine-positive urine testsDrug treatment programsAddiction treatment programsLAAM maintenanceAgonist therapyLine treatmentOpioid dependenceUrine testsTreatment responseDrug usersNEP attendersHeroin addictionProgram attendersAlcohol useSubscale scoresProgram entrySignificant reductionAttendersLAAM